Surmodics, Inc. (NASDAQ:SRDX) is scheduled to be announcing its earnings results before the market opens on Wednesday, July 26th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Surmodics has set its FY17 guidance at $0.15-0.25 EPS.

Surmodics (NASDAQ:SRDX) last announced its earnings results on Thursday, April 27th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by $0.02. Surmodics had a return on equity of 10.95% and a net margin of 12.88%. The business had revenue of $17.50 million for the quarter, compared to analyst estimates of $16.21 million. During the same quarter last year, the company posted $0.20 EPS. Surmodics’s quarterly revenue was up 4.8% on a year-over-year basis. On average, analysts expect Surmodics to post $0.22 EPS for the current fiscal year and $0.29 EPS for the next fiscal year.

Shares of Surmodics, Inc. (NASDAQ SRDX) opened at 28.20 on Wednesday. Surmodics, Inc. has a 52 week low of $21.90 and a 52 week high of $30.75. The stock’s 50 day moving average is $26.20 and its 200 day moving average is $24.60. The firm has a market cap of $374.38 million, a P/E ratio of 39.83 and a beta of 0.89.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/19/surmodics-inc-nasdaqsrdx-set-to-announce-earnings-on-wednesday.html.

SRDX has been the subject of a number of research analyst reports. Aegis initiated coverage on shares of Surmodics in a research note on Tuesday, June 27th. They issued a “buy” rating for the company. Zacks Investment Research lowered shares of Surmodics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. BidaskClub lowered shares of Surmodics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Lake Street Capital initiated coverage on shares of Surmodics in a research note on Friday, July 14th. They issued a “buy” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $34.33.

In other news, SVP Bryan K. Phillips sold 1,226 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $24.85, for a total value of $30,466.10. Following the completion of the sale, the senior vice president now directly owns 29,208 shares of the company’s stock, valued at approximately $725,818.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Gary R. Maharaj sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $28.03, for a total transaction of $140,150.00. Following the completion of the sale, the chief executive officer now directly owns 131,807 shares of the company’s stock, valued at $3,694,550.21. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,928 shares of company stock valued at $263,719. Company insiders own 6.40% of the company’s stock.

About Surmodics

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Earnings History for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.